Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | FABP7 | O15540 | 1/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29639589 | 1.00 | EPHX2 (0.42) | EPHX2KMT2AEPHX1CASP3KCNA5 | |
| SCHEMBL30466803 | 0.88 | EPHX2 (0.47) | EPHX2KMT2AEPHX1CASP3MDM4 | |
| SCHEMBL20530636 | 0.88 | EPHX2 (0.47) | EPHX2KMT2AEPHX1CASP3MDM4 | |
| SCHEMBL20530632 | 0.86 | EPHX2 (0.40) | EPHX2KMT2ACASP3MDM4TP53 | |
| SCHEMBL30466820 | 0.86 | EPHX2 (0.40) | EPHX2KMT2ACASP3MDM4TP53 | |
| SCHEMBL29639583 | 0.86 | EPHX1 (0.43) | EPHX2KMT2AEPHX1CASP3KCNA5 | |
| SCHEMBL20530637 | 0.85 | EPHX2 (0.42) | EPHX2KMT2AEPHX1CASP3MDM4 | |
| SCHEMBL30466801 | 0.85 | EPHX2 (0.42) | EPHX2KMT2AEPHX1CASP3MDM4 | |
| SCHEMBL2745029 | 0.82 | EPHX2 (0.47) | EPHX2KMT2AEPHX1CASP3MDM4 | |
| SCHEMBL20530643 | 0.81 | MTNR1A (0.42) | EPHX2KMT2ACASP3MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609905-B1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2022-06-08 | — | — | EP | disclosed |
| US-11091514-B2 | Peptide macrocycles and use thereof in the treatment of bacterial infections | HOFFMANN-LA ROCHE INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200040032-A1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN-LA ROCHE INC. (US) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091514-B2 | Peptide macrocycles and use thereof in the treatment of bacterial infections | VIP, NPY5R, CXCR3 | EPHX2 3891/4885KMT2A 4691/4885EPHX1 4139/4885 |
| US-20200040032-A1 | PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS | VIP, NPY5R, CXCR3 | EPHX2 3891/4885KMT2A 4691/4885EPHX1 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.